Tag Archives: Novartis

Merck and Novartis Down in Q3 Financial Reports

By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Posted in Deals, Global, Guest Blog, leadership | Also tagged , , , | Leave a comment

Will WHO Member States Pony Up for Neglected Diseases?

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. […]
Posted in Emerging Markets, Global, IP, leadership, Legal, Manufacturing, Market Access, pricing, R&D | Also tagged , , , , , , , , , | Leave a comment

Patent Filing to Drug Approval: A Difficult Journey Even for the Mighty

By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years. According to the law firm, only 129 “patent […]
Posted in Global, Guest Blog | Also tagged , | 1 Comment

GlaxoSmithKline Recalls Antihypertensive Drug Made at Novartis Facility

By Patricia Van Arnum. GlaxoSmithKline is recalling 394,230 bottles containing its antihypertensive drug DynaCirc CR (isradipine) controlled-release tablets, according to a Feb. 22, 2012, FDA enforcement report. The lots are being recalled due to concerns regarding the level of cGMP compliance and procedural controls related to line clearance during the packing process at the Lincoln, […]
Posted in Regulatory, Safety | Also tagged , , | 1 Comment

Merck KGaA MS Drug on the Fast Track

Merck KGaA received word July 25 that its application for the multiple sclerosis treatment Cladribine had received priority review status by FDA, decreasing the evaluation period from 10 months to six months, and closing the gap between Merck and the competition. “This is a critical milestone on the path to potential approval for short-course therapy […]
Posted in Strategy | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta